Alliances

Galapagos’ alliance strategy combines novel targets and candidate drugs discovered by Galapagos with patient expertise from Galapagos’ pharma partners.  Galapagos runs these programs until candidate drug, Phase 1 or Phase 2, at which point the partner has the option to license the program. 

 

Indication Partner Established
Inflammatory diseases  MorphoSys 2008
Osteoarthritis Servier 2010
Oncology Servier 2011
Rheumatoid arthritis/Crohn's disease  AbbVie  2012 
Cystic Fibrosis AbbVie 2013

 

 

© Copyright 2015 Galapagos NV | Disclaimer | General Purchase Terms 

 
Test